{{Drugbox
| IUPAC_name = 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
| image = Tazomeline.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 131987-54-7
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 131460
| ChemSpiderID = 116193
| ChEMBL = 131819
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = QDP6S14W5W

<!--Chemical data-->
| C=14 | H=23 | N=3 | S=2 
| molecular_weight = 297.48 g/mol
| smiles = n2snc(/C1=C/CCN(C)C1)c2SCCCCCC
}}

'''Tazomeline''' ('''LY-287,041''') is a [[drug]] which acts as a non-[[binding selectivity|selective]] [[muscarinic acetylcholine receptor]] [[agonist]].<ref name="pmid18082893">{{cite journal |vauthors=Langmead CJ, Watson J, Reavill C | title = Muscarinic acetylcholine receptors as CNS drug targets | journal = Pharmacology & Therapeutics | volume = 117 | issue = 2 | pages = 232–43 |date=February 2008 | pmid = 18082893 | doi = 10.1016/j.pharmthera.2007.09.009 | url = http://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00207-0}}</ref><ref name="doi10.1517/13543784.9.10.2259">{{cite journal | author = Amos D Korczyn | title = Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 10 | pages = 2259–2267(9) |date=October 2000 | doi = 10.1517/13543784.9.10.2259 | url = http://www.ingentaconnect.com/content/apl/eid/2000/00000009/00000010/art00004}}</ref> It was in [[clinical trial]]s for the treatment of [[cognitive deficit|cognitive dysfunction]] such as that seen in [[Alzheimer's disease]] and [[schizophrenia]], but development was apparently scrapped for unknown reasons.<ref name="pmid18082893"/><ref name="doi10.1517/13543784.9.10.2259"/><ref name="doi10.1023/A:1010474325601">{{cite journal |vauthors=Mashkovskii MD, Glushkov RG | title = Drugs for the Treatment of Alzheimer's Disease | journal = Pharmaceutical Chemistry Journal | volume = 35 | issue = 4 | pages = 179–182 |date=April 2001 | doi = 10.1023/A:1010474325601 | url = http://www.springerlink.com/content/w5vq328733t2v601/}}</ref>

== See also ==
* [[Alvameline]]
* [[Milameline]]
* [[Sabcomeline]]
* [[Xanomeline]]

== References ==
{{Reflist}}

{{Nootropics}}
{{Anti-dementia drugs}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic agonists]]
[[Category:Tetrahydropyridines]]
[[Category:Thiadiazoles]]